Contepo Injection, Powder, For Solution
NDC Package 71288-035-52

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Contepo (fosfomycin disodium) injection is cONTEPO is contraindicated in patients with known serious hypersensitivity to fosfomycin, or any of the excipients [see Warnings and Precautions (5.2)]. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Meitheal Pharmaceuticals Inc., this product is identified by NDC 71288-035 and is authorized under FDA application NDA212271.

Identification & Billing

NDC Package Code
71288-035-52
Package Description
12 VIAL, GLASS in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, GLASS (71288-035-51)
Product Code
71288-035
11-Digit Billing Format
71288003552
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
12 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Contepo
Non-Proprietary Name
Fosfomycin Disodium
Substance Name
Fosfomycin Sodium
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
FOSFOMYCIN SODIUM 6 g/1
Usage Information
CONTEPO is contraindicated in patients with known serious hypersensitivity to fosfomycin, or any of the excipients [see Warnings and Precautions (5.2)].

Regulatory & Marketing

Labeler Name
Meitheal Pharmaceuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA212271
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-22-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71288-035-52 identifies a specific commercial package of 12 vial, glass in 1 carton / 1 injection, powder, for solution in 1 vial, glass (71288-035-51) of Contepo, a human prescription drug labeled by Meitheal Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 12 billable units per package. This injection, powder, for solution is formulated for intravenous use and contains fosfomycin sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Meitheal Pharmaceuticals Inc. on October 22, 2025. The current certification is valid through December 31, 2026.

How is this Meitheal Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71288003552. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 12 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71288-035-52
11-Digit CMS (5-4-2)
71288-0035-52

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.